Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy | MicrobiomeTrials← Back to trialsNCT04440280
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2020-09-16Est. Completion: 2027-04-29
Enrollment target: 45 participants Locations- Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, United States
Other microbiome trials you might be interested in
Fuchs Endothelial Corneal DystrophyCataractGlaucoma
The goal of this study is to learn if topical ROCK inhibitors protect endothelial corneal cells in patients with glaucom…
Zagreb, CroatiaCompleted Dec 1, 2026
CataractFuchs Endothelial Corneal Dystrophy
Study Overview
This study aims to evaluate the visual outcomes, quality of vision, and patient satisfaction after recei…
Leuven, BelgiumEst. completion Sep 2028